Success Metrics

Clinical Success Rate
42.9%

Based on 3 completed trials

Completion Rate
43%(3/7)
Active Trials
0(0%)
Results Posted
200%(6 trials)
Terminated
4(44%)

Phase Distribution

Ph not_applicable
5
56%
Ph phase_1
1
11%
Ph phase_4
2
22%
Ph phase_2
1
11%

Phase Distribution

1

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
1(11.1%)
Phase 4Post-market surveillance
2(22.2%)
N/ANon-phased studies
5(55.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

33.3%

3 of 9 finished

Non-Completion Rate

66.7%

6 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(3)
Terminated(6)

Detailed Status

Terminated4
Completed3
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
42.9%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (11.1%)
Phase 21 (11.1%)
Phase 42 (22.2%)
N/A5 (55.6%)

Trials by Status

terminated444%
withdrawn222%
completed333%

Recent Activity

0 active trials
Showing 5 of 9
terminatedphase_4

Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1

NCT03738878
completedphase_4

Nebivolol and Endothelial Regulation of Fibrinolysis (NERF)

NCT01595516
terminatedphase_2

Endothelial Hyperpolarization in Humans

NCT00166166
terminatedphase_1

Tissue-Type Plasminogen Activator (t-PA) Release Predicts Major Adverse Cardiac Events (MACE) in Patients With Non-critical Coronary Artery Disease

NCT00868855
terminatednot_applicable

Characterization of Brachial Arterial t-PA Release, Endothelial Function, Obesity and Inflammation

NCT00780481
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT03738878Phase 4

Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1

Terminated
NCT01595516Phase 4

Nebivolol and Endothelial Regulation of Fibrinolysis (NERF)

Completed
NCT00166166Phase 2

Endothelial Hyperpolarization in Humans

Terminated
NCT00868855Phase 1

Tissue-Type Plasminogen Activator (t-PA) Release Predicts Major Adverse Cardiac Events (MACE) in Patients With Non-critical Coronary Artery Disease

Terminated
NCT00780481Not Applicable

Characterization of Brachial Arterial t-PA Release, Endothelial Function, Obesity and Inflammation

Terminated
NCT00780377Not Applicable

Intracoronary Bradykinin Mediated t-PA Release in Heart Transplant Recipients

Withdrawn
NCT00780637Not Applicable

Brachial Artery t-PA Release in Heart Transplant Recipients

Withdrawn
NCT02189122Not Applicable

Comparative Effects of Aspirin and NHP-544C

Completed
NCT01413542Not Applicable

Pharmacogenetics of Ace Inhibitor-Associated Angioedema

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9